FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1819-1821 June 6, 2002 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Gaspoz, J.-M. PubMed Citation

In this issue of the Journal, Gaspoz et al.¹ examine the relative benefits of various therapeutic strategies for the secondary prevention of coronary heart disease. This is a critical area of inquiry, given the unenviable position of heart disease as the principal cause of death in the developed world. Antiplatelet therapy has been clearly shown to be effective in the secondary prevention of vascular morbidity in patients who have shown themselves to be at risk through the occurrence of a primary event such as a myocardial infarction or stroke. Such patients and their physicians are now in the fortunate position . . . [Full Text of this Article]

References

Related Letters:

Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Disease
Akinlade B. K., de Lemos J. A., McGuire D. K., Armstrong E. C., Ramsey S. D., Yaes R. J., Gaspoz J.-M., Coxson P., Goldman L., Wood A. J.J.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:560-563, Feb 6, 2003. Correspondence

This article has been cited by other articles:

• Califf, R. M., Harrington, R. A., Madre, L. K., Peterson, E. D., Roth, D., Schulman, K. A. (2007). Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics. Health Aff (Millwood) 26: 62-74 [Abstract] [Full Text]  
• Watanabe, A. M., Dollens, R. W., Malatestinic, W. N., Browne, R. A. (2004). Is a Paradigm Shift in US Healthcare Reimbursement Inevitable?. Circulation 109: 1456-1459 [Full Text]  
• Davidson, B. L., Sullivan, S. D., Kahn, S. R., Borris, L., Bossuyt, P., Raskob, G. (2003). The Economics of Venous Thromboembolism Prophylaxis: A Primer for Clinicians. Chest 124 : 393S-396S [Abstract] [Full Text]  
• Colwell, J. A., Nesto, R. W. (2003). The Platelet in Diabetes: Focus on prevention of ischemic events. Diabetes Care 26: 2181-2188 [Abstract] [Full Text]  
• Gildea, T. R., Shermock, K. M., Singer, M. E., Stoller, J. K. (2003). Cost-Effectiveness Analysis of Augmentation Therapy for Severe {alpha}1-Antitrypsin Deficiency. Am. J. Respir. Crit. Care Med. 167: 1387-1392 [Abstract] [Full Text]  
• Akinlade, B. K., de Lemos, J. A., McGuire, D. K., Armstrong, E. C., Ramsey, S. D., Yaes, R. J., Gaspoz, J.-M., Coxson, P., Goldman, L., Wood, A. J.J. (2003). Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Disease. NEJM 348: 560-563 [Full Text]  
• (2002). Cost-Effectiveness of Aspirin and Clopidogrel. Journal Watch Cardiology 2002: 1-1 [Full Text]